Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Nanomolar Potency

Published: Friday, April 13, 2012
Last Updated: Friday, April 13, 2012
Bookmark and Share
This article looks at prediction of cancer drug efficacy in its ultimate user, the human patient and reviews current knowledge followed by illustrative examples that, in the absence of definitive data, provide an empirical perspective.

Abstract
In the current paradigm of anticancer drug development, candidate compounds are evaluated by testing their in vitro potency against molecular targets relevant to carcinogenesis; their effect on cultured cancer cells; and their ability to inhibit cancer growth in animal models. We discuss the key assumptions inherent in these approaches. In recent years, great emphasis has been placed on selecting for development compounds with nanomolar in vitro potency, expecting that they will be efficacious and safer based on the assumption that they can be used at lower doses (“the nanomolar rule”). However, this rule ignores critical parameters affecting efficacy and toxicity such as physiochemical and ADMET properties, off-target effects and multi-targeting activities. Thus, uncritical application of the nanomolar rule may reject efficacious compounds or select ineffective or toxic compounds. We present examples of efficacious chemotherapeutic (alkylating agents, hormonal agents, antimetabolites, thalidomide and valproic acid) and chemopreventive (aspirin and sulindac) agents having millimolar potency, and of compounds with nanomolar potency (COX-2 inhibitors) that, nevertheless, failed or proved unsafe. The effect of candidate drugs on animal models of cancer is a better predictor of human drug efficacy; particularly useful are tumor xenografts. Given the cost of failure at clinical stages, it is imperative to keep in mind the limitations of the nanomolar rule and to employ relevant in vivo models early in drug discovery to prioritize candidates. Although in vivo models will continue having a major role in cancer drug development, more robust approaches that combine high predictive ability with simplicity and low cost should be developed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Genetics Behind Abdominal Pigmentation in Drosophila melanogaster
This study by researchers at the North Carolina State University provides evidence that genetic variation at a number of steps in regulatory, developmental, and transport pathways may contribute to natural variation in abdominal pigmentation.
Wednesday, May 06, 2015
Mosquitoes Resistant to DDT Also Resistant to Mosquito Net Insecticide
Understanding how resistance works will help to develop tests, stopping resistance genes from spreading amongst mosquito populations.
Thursday, February 27, 2014
The Role of Mass Spectrometry in the "Omics" Era
The tremendous developments of the MS technology and concurrent gene sequencing efforts have made the “-omic” revolution possible.
Tuesday, February 18, 2014
Epigenetic Regulation of ADME-Related Genes: Focus on Drug Metabolism and Transport
As research in epigenetic regulation of ADME genes progresses, there are many opportunities and challenges in understanding the epigenetic mechanisms in drug metabolism and disposition.
Monday, September 23, 2013
Applications of Metabolomics in Cancer Research
This review focuses on specific areas within cancer and carcinogenesis research on which metabolomics has been brought to bear.
Monday, July 22, 2013
Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics
This study explores a new approach to seeking biomarkers for prostate cancer and other diseases.
Monday, April 08, 2013
'Omics' Approaches to Understanding Interstitial Cystitis/Painful Bladder Syndrome/Bladder Pain Syndrome
This review describes the current state of 'omics' studies and available data sets relevant to IC/PBS/BPS.
Monday, March 11, 2013
Systems Biology Approaches and Applications in Obesity, Diabetes, and Cardiovascular Diseases
This article summarizes systems biology methodologies that can produce novel mechanistic insights, identify disease biomarkers, and uncover potential therapeutic targets from a combination of omics datasets.
Thursday, February 21, 2013
Anti-cancer Drug Discovery and Development: Bcl-2 Family Small Molecule Inhibitors
In this article, researchers from The Pennsylvania University College of Medicine discuss the current status of Bcl-2 family small molecule inhibitors in preclinical and clinical development.
Thursday, January 31, 2013
Remodeling of Central Metabolism in Invasive Breast Cancer Compared to Normal Breast Tissue
Researchers from Charité University Hospital have constructed the first comprehensive metabolic map of breast cancer by GC-TOF analysis of a large cohort of breast cancer and normal tissues.
Friday, September 07, 2012
SIGLa: An Adaptable LIMS for Multiple Laboratories
SIGLa has been developed with the aim of contributing to complex data management in the laboratory by managing large amounts of data and guaranteeing its consistency.
Monday, August 20, 2012
Genomic Assessment of Human Cumulus Cell Marker Genes
Study includes the investigation of the impact of technical and biological variability such as qPCR series and patients on the level of gene expression.
Thursday, August 02, 2012
MALDI Imaging Mass Spectrometry for In Situ Proteomic Analysis of Preneoplastic Lesions in Pancreatic Cancer
Researchers from Technische Universität München have shown MALDI-IMS on sections from endogenous mouse models of PDAC is a valuable approach for proteomic investigations of diseased tissue.
Monday, July 16, 2012
Prediction of Gastric Cancer Metastasis through Urinary Metabolomic Investigation using GC/MS
This aim of this article is to gain new insights into tumor metabolism and to identify possible biomarkers with potential diagnostic values to predict tumor metastasis.
Monday, July 16, 2012
New Study using Large-scale Gene Expression Microarray Analysis
Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Friday, June 15, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!